G.K. Hunter
About
G.K. Hunter is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Radiation.
According to data from OpenAlex, G.K. Hunter has authored 25 papers receiving a total of 429 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 12 papers in Genetics and 7 papers in Radiation. Recurrent topics in G.K. Hunter's work include Glioma Diagnosis and Treatment (12 papers), Brain Metastases and Treatment (8 papers) and Advanced Radiotherapy Techniques (7 papers). G.K. Hunter is often cited by papers focused on Glioma Diagnosis and Treatment (12 papers), Brain Metastases and Treatment (8 papers) and Advanced Radiotherapy Techniques (7 papers). G.K. Hunter collaborates with scholars based in United States, Canada and Latvia. G.K. Hunter's co-authors include C.A. Reddy, Shlomo A. Koyfman, Lilyana Angelov, Samuel T. Chao, John H. Suh, Jerrold P. Saxton, T. Djemil, Ehsan H. Balagamwala, Mohammad K. Khan and Robert J. Weil and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Radiation Oncology*Biology*Physics.
In The Last Decade
G.K. Hunter
23 papers receiving 425 citations
Peers
G.K. Hunter
Eric Yi-Liang Shen Taiwan
Mark J. Amsbaugh United States
Charn Il Park South Korea
Sei‐Chul Yoon South Korea
Roman O. Kowalchuk United States
Alan Schulsinger United States
Matthew J. Ferris United States
R.C. Fogaroli Brazil
Sandra Röddiger Germany
Rovel Colaco United Kingdom
Citations per year, relative to G.K. Hunter G.K. Hunter (= 1×)
peers
Eric Yi-Liang Shen
Countries citing papers authored by G.K. Hunter
Since
Specialization
Citations
This map shows the geographic impact of G.K. Hunter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G.K. Hunter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G.K. Hunter more than expected).
Fields of papers citing papers by G.K. Hunter
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by G.K. Hunter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G.K. Hunter. The network helps show where G.K. Hunter may publish in the future.
Co-authorship network of co-authors of G.K. Hunter
This figure shows the co-authorship network connecting the top 25 collaborators of G.K. Hunter. A scholar is included among the top collaborators of G.K. Hunter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G.K. Hunter. G.K. Hunter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fleming, Jessica L., Stephanie L. Pugh, Susan M. Chang, et al.. (2025). Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma. International Journal of Radiation Oncology*Biology*Physics. 123(1). 84–92.
2.
Scheurer, Michael E., Renke Zhou, Mark R. Gilbert, et al.. (2022). Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825. Neuro-Oncology Advances. 4(1). vdac152–vdac152.
3.
Wefel, Jeffrey S., Terri S. Armstrong, Stephanie L. Pugh, et al.. (2021). Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825). Neuro-Oncology. 23(7). 1125–1138.
4.
Fleming, Jessica L., S. Pugh, Erica H. Bell, et al.. (2020). Prognostic Significance of IDH1/2 Mutation and MGMT Promoter Methylation Status in RTOG 9813. International Journal of Radiation Oncology*Biology*Physics. 108(5). 1399–1399.
5.
Bell, Erica H., Minhee Won, Jessica L. Fleming, et al.. (2019). Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802.. Journal of Clinical Oncology. 37(15_suppl). 2002–2002.
6.
Blumenthal, Deborah T., Minhee Won, Minesh P. Mehta, et al.. (2018). Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. Neuro-Oncology. 20(7). 966–974.
7.
Bell, Erica H., Minhee Won, Susan M. Chang, et al.. (2017). MGMT Promoter Methylation Status Independently Predicts Overall Survival in Anaplastic Astrocytoma in NRG Oncology/RTOG 9813: A Phase 3 Trial of Radiation Plus Nitrosourea Versus Radiation Plus Temozolomide. International Journal of Radiation Oncology*Biology*Physics. 99(2). S99–S100.
8.
Tendulkar, Rahul D., G.K. Hunter, C.A. Reddy, et al.. (2013). Causes of Mortality After Dose-Escalated Radiation Therapy and Androgen Deprivation for High-Risk Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 87(1). 94–99.
9.
Hunter, G.K., Lisa Rybicki, Aaron P. Hoschar, et al.. (2013). Oropharyngeal squamous cell carcinoma with known human papillomavirus status treated with definitive chemoradiotherapy: patterns of failure and toxicity outcomes. Radiation Oncology. 8(1). 174–174.
10.
Hunter, G.K., Ehsan H. Balagamwala, Shlomo A. Koyfman, et al.. (2012). The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma. Practical Radiation Oncology. 2(4). e95–e100.
11.
Khan, Mohammad K., Shlomo A. Koyfman, G.K. Hunter, C.A. Reddy, & Jerrold P. Saxton. (2012). Definitive radiotherapy for early (T1-T2) Glottic Squamous cell carcinoma: a 20 year Cleveland clinic experience. Radiation Oncology. 7(1). 193–193.
12.
Balagamwala, Ehsan H., Lilyana Angelov, Shlomo A. Koyfman, et al.. (2012). Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma. Journal of Neurosurgery Spine. 17(6). 556–564.
13.
Hunter, G.K., C.A. Reddy, Eric A. Klein, et al.. (2012). Long-Term (10-Year) Gastrointestinal and Genitourinary Toxicity after Treatment with External Beam Radiotherapy, Radical Prostatectomy, or Brachytherapy for Prostate Cancer. SHILAP Revista de lepidopterología. 2012. 1–7.
14.
Hunter, G.K., C.A. Reddy, Sana Rehman, et al.. (2012). Late toxicity after intensity modulated and image guided radiation therapy for localized prostate cancer and post-prostatectomy patients. Practical Radiation Oncology. 3(4). 323–328.
15.
Hunter, G.K., John H. Suh, Alwyn M. Reuther, et al.. (2011). Treatment of Five or More Brain Metastases With Stereotactic Radiosurgery. International Journal of Radiation Oncology*Biology*Physics. 83(5). 1394–1398.
16.
Hunter, G.K., Ehsan H. Balagamwala, Shlomo A. Koyfman, et al.. (2011). The Efficacy of External Beam Radiotherapy and Stereotactic Body Radiotherapy (SBRT) for Painful Spinal Metastases from Renal Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 81(2). S649–S650.
17.
Hunter, G.K., C.A. Reddy, Kenneth W. Angermeier, et al.. (2010). Long-term (potential 10 year follow-up) Toxicity after Treatment for Prostate Cancer with Either External Beam Radiation Therapy, Interstitial Brachytherapy, or Radical Prostatectomy. International Journal of Radiation Oncology*Biology*Physics. 78(3). S354–S354.
18.
Hunter, G.K., John H. Suh, Gene H. Barnett, et al.. (2009). Treatment of Five or More Brain Metastases with Stereotactic Radiosurgery. International Journal of Radiation Oncology*Biology*Physics. 75(3). S504–S504.
19.
Sheng, Ke, et al.. (2008). Is daily computed tomography image guidance necessary for nasal cavity and nasopharyngeal radiotherapy? An investigation based on helical tomotherapy. Journal of Applied Clinical Medical Physics. 9(1). 36–46.
20.
Hunter, G.K., Kevin J. Ashton, & B.J. Merry. (1987). In vitro sensitivity of human ovarian tumors to chemotherapeutic agents with adjuvant danazol.. PubMed. 69(2). 233–6.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Eric Yi-Liang Shen Breakdown of academic impact, for papers by Mark J. Amsbaugh Breakdown of academic impact, for papers by Charn Il Park Breakdown of academic impact, for papers by Sei‐Chul Yoon Breakdown of academic impact, for papers by Roman O. Kowalchuk Breakdown of academic impact, for papers by Alan Schulsinger Breakdown of academic impact, for papers by Matthew J. Ferris Breakdown of academic impact, for papers by R.C. Fogaroli Breakdown of academic impact, for papers by Sandra Röddiger Breakdown of academic impact, for papers by Rovel Colaco